A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study

Metastatic Solid Tumors Clinical Trial

— NTRK  

Official title:

A Study to Determine the Incidence of NTRK Fusions in Subjects With Locally Advanced/Unresectable or Metastatic Solid Tumors With NTRK Fusions and Related Treatment Outcomes.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04010240
• Other study ID #: IB2015-NTRK
• Secondary ID: MR 0112040319
• Status: Completed
• Start date: December 23, 2015
• Est. completion date: December 1, 2020

Study information

• Verified date: August 2022
• Source: Institut Bergonié
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis.

Description:

This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis. The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the NTRK1, NTRK2 and NTRK3 genes, respectively. These receptor tyrosine kinases are expressed in human neuronal tissue and play an essential role in the physiology of development and function of the nervous system through activation by neurotrophins. Gene fusions involving NTRK genes lead to transcription of chimeric Trk proteins with constitutively activated or overexpressed kinase function conferring oncogenic potential. These genetic abnormalities have recently emerged as targets for cancer therapy, because novel compounds have been developed that are selective inhibitors of the constitutively active rearranged proteins. Developments in this field are being aided by next generation sequencing methods as tools for unbiased gene fusions discovery. However, the incidence of NTRK aberrations in solid tumors is unknown as well as the natural history of NTRK-rearranged tumors This study will provide better knowledge of NTRK gene fusion incidence to allow recommendations for pathological diagnosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3820
• Est. completion date: December 1, 2020
• Est. primary completion date: December 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Month and older

Eligibility

Inclusion Criteria:

• Age = 1 month.

• Subject has/had a histologically or cytologically confirmed diagnosis of solid tumor including but not exclusively: soft tissue sarcoma, BRAF wild type melanoma, KRAS wild-type colorectal cancer, central nervous system, EGFR-wild type non-small cell lung cancer.

• Subject has locally advanced/unresectable or metastatic disease.

• Subject has received at least one systemic anti-cancer therapy for locally advanced/unresectable or metastatic disease for which there is available outcome information in terms of PFS, or the latter can be estimated based on the subject's records.

• Subject has tumor material available for immunoscreening (IHC for NTRK gene fusions).

• Written and voluntary informed consent understood, signed and dated, or a waiver of consent is granted according to French régulations.

Exclusion Criteria:

• Subjects who have not yet received or completed at least one systemic anti-cancer therapy for locally advanced/unresectable or metastatic cancer.

Related Conditions & MeSH terms

• Metastatic Solid Tumors

Intervention

Other:
• Retrospective cohort
Tumor material tested positive will be analyzed by next-generation sequencing to identify NTRK1, NTRK2 or NTRK3 gene fusions.

Locations

Country	Name	City	State
France	Institut Bergonié	Bordeaux	Aquitaine

Sponsors (2)

Lead Sponsor	Collaborator
Institut Bergonié	Bayer

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of NTRK fusions in subjects with locally advanced/unresectable or metastatic solid tumors.		Retrospective analysis between January 2019 and December 2020
Secondary	Treatment outcome in terms of objective response rate.	ORR will be defined as the proportion of patients with objective response (complete or partial response) during the first-line anti-cancer therapy.	Retrospective analysis between January 2019 and December 2020
Secondary	Treatment outcome in terms of progression-free survival.	PFS will be defined as the delay from the date of onset of first-line anti-cancer therapy to the date of progression.	Retrospective analysis between January 2019 and December 2020
Secondary	Treatment outcome in terms of overall survival	OS will be defined as the delay from the date of start first-line anti-cancer therapy to the date of death (whatever the cause).	Retrospective analysis between January 2019 and December 2020